Moderna Inc. surged 14.36% on Tuesday to close at $158.83 after Wolfe Research raised its rating on the stock to Peer Perform from Underperform. The $19.94 increase boosted Moderna's quoted equity value by approximately $8.0 billion.
Stock move, valuation, trial evidence and cash runway
Financial figures reported July 31, 2026. A $950M settlement payment followed in July.
S&P Global consensus: Hold, 23 analysts; average target implies 37.2% downside from Tuesday's close.
| Measure | Reading | Investor meaning |
|---|---|---|
| INTerpath-001 enrollment | 1,137 patients | First positive Phase 3 individualized mRNA cancer-therapy readout |
| Treatment design | Up to 34 neoantigens; nine intismeran doses | Patient-specific manufacturing adds cost and turnaround risk |
| Phase 2b five-year result | 49% lower recurrence/death risk; 59% lower distant-metastasis/death risk | Supports mechanism, but Phase 3 effect size remains undisclosed |
| Moderna reaction | +176.97% on Aug. 19 | Largest direct platform repricing |
| Merck reaction | +12.6% on Aug. 19 | Extends the Keytruda franchise opportunity |
| BioNTech reaction | about +22% on Aug. 19 | Read-through for personalized mRNA oncology |
The August 25 rally added about $8.0 billion in value. Since the pre-readout close, the gain is about $38.3 billion. That premium now depends on regulatory timing, manufacturing economics and success beyond melanoma.
Hazard ratios, absolute event rates and overall-survival data are pending. Personalized production may constrain margins. Other tumors may not reproduce the melanoma result. Cash burn remains material.
Market data as of August 21, 2026, 16:00 EDT (22:00 CEST). U.S. market closed.
| Firm | Rating | Target | Gap |
|---|---|---|---|
| BofA | Hold | $170 | +17.1% |
| UBS | Hold | $150 | +3.4% |
| Goldman | Hold | $120 | -17.3% |
| Morgan Stanley | Hold | $89 | -38.7% |
| Consensus | Neutral | $78.78 | -45.7% |
| Phase 3 patients | 1,137 |
| Prior Phase 2b recurrence/death reduction | 49% |
| Q2 revenue | $145M |
| Q2 GAAP net loss | $782M |
| June cash and investments | $6.9B |
| 2026 year-end cash outlook | $4.7B-$5.2B |
Sources: Moderna and Merck Phase 3 release, Moderna Q2 2026 SEC filing, Nasdaq/Yahoo Finance closing data, Investing.com analyst targets, S3 Partners estimate reported by Business Times. Percentages are calculated from cited closes and targets. This dashboard is informational, not investment advice.
Merck's value gain was nearly 18 times one published valuation for the melanoma program.
A melanoma approval is only the first layer. The premium also reflects Keytruda lifecycle extension and shots in other tumors.
$8.37 billion of Q2 sales came from the Keytruda franchise—50.4% of Merck's $16.61 billion total.
The average target sat 11.2% below the intraday price. Even the high target offered just 1.2% upside.
S&P 500 • INDEXSP:SPX
Intraday, not a closing value
+45.89 points
-53.30 points
Wednesday gain ÷ Tuesday loss
Technology carried a 36.8% S&P 500 weight on July 31. Healthcare held 9.1%.
| Firm | Target | Upside | Stance |
|---|---|---|---|
| Citigroup | 8,100 | 4.7% | Constructive |
| JPMorgan | 8,000 | 3.4% | Constructive |
| Goldman Sachs | 8,000 | 3.4% | Constructive |
| UBS | 7,900 | 2.1% | Constructive |
Upside is measured against 7,737.65. “Constructive” summarizes targets above the market, not a formal index rating.
| Metric | Value |
|---|---|
| Q2 revenue | $145M |
| Q2 GAAP net loss | $(782)M |
| June 30 cash & investments | $6.9B |
| July settlement payment | $(950)M |
| 2026 year-end cash guide | $4.7–5.2B |
